Waters receives FDA clearance for two BD OneFlow blood cancer tests
Waters announced FDA 510(k) clearance for BD OneFlow LST and B-CLPD T1 flow cytometry tests. The ready-to-use tests are intended to help identify B-cell non-Hodgkin lymphoma, including CLL, and report 96.3% sensitivity and 98.2% specificity for CLL. They reduce manual steps by about 95% and are expected to launch commercially in the U.S. in spring 2027.
Waters acquires MOBILion Systems to expand mass spectrometry and proteomics
Waters acquired MOBILion Systems and its SLIM high-resolution ion-mobility technology, expanding Waters’ mass spectrometry portfolio and proteomics capabilities. The combined platform is intended to improve complex protein analysis, biomarker discovery, and high-throughput AI-enabled research workflows. Waters plans to integrate the technology with its instruments and software; financial terms were not disclosed.
Waters raises 2026 guidance after third-quarter revenue reaches $1.767 billion
Waters reported third-quarter revenue of $1.767 billion and adjusted EPS of $4.10, up 21% year over year and above analyst estimates. Organic constant-currency revenue grew 10%, with strength in consumables and instruments. The company raised its 2026 revenue and adjusted EPS guidance, citing demand and acquisition integration; it also outlined expectations for 2027 growth and margin expansion.
Valuation analysis puts Waters shares 27% above estimated intrinsic value
A discounted cash flow estimate suggested Waters shares at $459.90 were about 27% above intrinsic value. The analysis said projected value depends heavily on future cash generation, while recent Q3 results, raised revenue guidance, AI-enabled products, and the BD acquisition support investor optimism. Community valuation scenarios ranged from 13% undervalued to roughly fairly valued, and the analysis cited three warning signs.
Waters’ valuation analysis weighs growth against earnings and integration risks
Waters reported third-quarter sales of $1.767 billion, up from $800 million a year earlier, while net income fell to $81 million from $149 million. For the first nine months, sales rose to $4.678 billion, but the company recorded a $127 million loss. The article cited valuation concerns alongside growth in chemistry columns and GLP-1 testing, and risks from BD integration and acquired China operations.
Waters’ Q3 beat and raised guidance reshape its investment case
Waters reported Q3 2026 sales of US$1.77 billion and diluted EPS of US$0.82, raised full-year guidance, and completed its acquisition of MOBILion Systems to expand mass spectrometry and proteomics capabilities. The article noted revenue growth alongside a sharp year-over-year EPS decline and a nine-month net loss, and discussed potential benefits from AI features in Empower Software and uncertainty around adoption.
Waters was expected to report third-quarter results, with analysts forecasting 119% year-over-year revenue growth. The previous quarter’s revenue rose 113% to $1.65 billion and narrowly beat estimates, while next-quarter revenue guidance met expectations. Analysts had largely maintained estimates over the past month, and Waters shares had gained 5.1% during that period.